BeOne gains Asian rights to Revolution’s RAS(ON) inhibitors and will test them with its own oncology drugs against some of cancer’s hardest targets.
The radiodiagnostic lets PET scans visualize tau neurofibrillary tangles — a core hallmark of Alzheimer’s — complementing existing amyloid imaging in patients being evaluated for the disease.
The Phase 3 PreVenTB study of more than 12,000 people found the vaccines helped only certain groups against certain forms of tuberculosis — underscoring how hard a better TB shot remains.
Expressable becomes the first speech-therapy provider on Amazon’s Health Benefits Connector, which matches shoppers to digital-health services their employer plans already cover.
The antibody cut new abnormal bone formation by up to 90% in a trial for fibrodysplasia ossificans progressiva — a devastating disorder in which soft tissue slowly turns to bone.
New data add to the case that simpler two-drug therapy works as well as the standard three-drug combination for people starting HIV treatment.
Vitestro’s Aletta autonomously finds a vein and draws blood in adults, with one trained phlebotomist supervising up to three machines — a possible answer to a worsening staffing shortage.
The Raleigh biotech priced its Nasdaq debut at $13 a share to fund mizagliflozin, an oral drug aimed at the dangerous blood-sugar crashes some patients face after bariatric surgery.
Kobe University researchers mass-produced iPSC-derived γδ T cells that cut tumor weight by up to 88% in mice — a step toward cheaper, ready-made cell therapy.
The personalized vaccine plus Keytruda cut the risk of melanoma returning after surgery — the first positive Phase 3 result for an mRNA-based, individualized cancer vaccine.
Gladstone scientists engineered human interneurons from stem cells and used them to repair the nerve pathways that control breathing after spinal cord injury.
Columbia engineers linked lab-grown human bone and lung tissue on a chip and watched circulating breast-cancer cells choose their targets — and soften them up in advance.